Copyright
©The Author(s) 2023.
World J Diabetes. Aug 15, 2023; 14(8): 1314-1322
Published online Aug 15, 2023. doi: 10.4239/wjd.v14.i8.1314
Published online Aug 15, 2023. doi: 10.4239/wjd.v14.i8.1314
Parameter | Number of patients, n = 169 |
Age (± SD), yr | 51.7 (13.8) |
Gender, n (%) | Females, 92 (54.4) |
Males, 77 (45.6) | |
Type of diabetes, n (%) | Type I, 18 (10.7) |
Type II, 149 (88.2) | |
Not mentioned, 2 (1.1) | |
Body mass index (± SD) | 29.6 (6.4) |
Clinical presentation, n (%) | Nausea/Vomiting, 110 (65.1) |
Abdominal pain, 63 (37.3) | |
Breathlessness, 52 (30.8) | |
Fatigue, 46 (27.2) | |
Altered mental status, 34 (20.1) | |
Loss of consciousness, 11 (6.5) | |
Chest pain, 5 (3) | |
Shock, 4 (2.4) | |
Fever, 4 (2.4) | |
Others, 12 (7.1) | |
Comorbidities, n (%) | Diabetes, 166 (98.2) |
Hypertension, 45 (26.6) | |
Coronary artery disease, 20 (11.8) | |
Dyslipidemia, 13 (7.7) | |
Cancer, 4 (2.4) | |
Others, 24 (14.4) | |
SGLT-2 inhibitor involved, n (%) | Empagliflozin, 79 (46.8) |
Canagliflozin, 50 (29.6) | |
Dapagliflozin, 39 (23.1) | |
Ipragliflozin, 1 (0.6) | |
Tofogliflozin, 1 (0.6) | |
Other OHAs prescribed, n (%) | Yes, 135 (79.9) |
No, 25 (14.8) | |
Not mentioned, 9 (5.1) | |
Other diabetes medications involved, n (%) | Metformin, 119 (70.4) |
Dipeptidyl peptidase 4 inhibitors, 42 (24.9) | |
Sulfonylureas, 26 (15.4) | |
Thiazolidinediones, 10 (5.9) | |
Meglitinides, 3 (1.8) | |
α-Glucosidase inhibitors, 2 (1.2) | |
Insulins, 57 (33.7) | |
Glucagon-like peptide-1 receptor agonist, 21 (12.4) | |
Not mentioned, 11 (6.5) | |
History of alcohol use, n (%) | 6 (3.6) |
Identifiable triggering factor, n (%) | Present, 133 (78.7) |
Triggering factor, n (%) | Infection, 64 (37.9) |
Major surgery, 41 (24.3) | |
Reduced food intake, 32 (18.9) | |
Any major illness, 17 (10.1) | |
Reduced carbohydrate/ketogenic diet 14 (8.3) | |
Dehydration, 14 (8.3) | |
Reduced insulin dosages, 10 (5.9) | |
Prolonged fasting, 9 (5.3) | |
Trauma, 2 (1.2) | |
Ketones for diagnosis, n (%) | Only urine, 62 (36.7) |
Only plasma, 36 (21.3) | |
Both, 60 (35.5) | |
Not mentioned, 11 (6.5) | |
Organ failure, n (%) | Respiratory, 20 (11.8) |
Cardiac, 11 (6.5) | |
Renal, 8 (4.7) | |
Need for organ support, n (%) | Invasive mechanical ventilation, 22 (13) |
Vasopressors, 11 (6.5) | |
RRT, 10 (5.9) | |
Other treatments given, n (%) | Sodium bicarbonate, 21 (12.4) |
Need for ICU, n (%) | 104 (61.5) |
Days in ICU (± SD) | 3.4 (5.4) d |
Days in hospital (± SD) | 9.3 (10.4) d |
Outcome, n (%) | Alive, 164 (97) |
Death, 4 (2.4) | |
Not mentioned, 1 (0.6) |
Parameter | Median values |
Blood glucose (IQR) | 184.5 (151.8-219.3) mg/dL |
Serum osmolality (IQR) | 297 (290.8-312.8) mmol/kg |
pH (IQR) | 7.14 (7.05-7.24) |
Bicarbonate (IQR) | 8.6 (6-11) mmol/L |
Lactates (IQR) | 1.3 (1.1-1.8) mmol/L |
Anion gap (IQR) | 22.50 (19-28) mmol/L |
- Citation: Juneja D, Nasa P, Jain R, Singh O. Sodium-glucose Cotransporter-2 Inhibitors induced euglycemic diabetic ketoacidosis: A meta summary of case reports. World J Diabetes 2023; 14(8): 1314-1322
- URL: https://www.wjgnet.com/1948-9358/full/v14/i8/1314.htm
- DOI: https://dx.doi.org/10.4239/wjd.v14.i8.1314